Drug Trial Radar · NCT05646862
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Jun 7, 2023
Primary completion
Nov 13, 2026
Study completion Mar 30, 2029
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK3CA-mutated, locally advanced (LA) or metastatic breast cancer (mBC), who progressed during or after cyclin dependent kinase 4/6i (CDK4/6i)-based therapy. Enrollment for the main study is now complete.
Conditions
- Breast Cancer
Interventions
InavolisibDrug
Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle of main study and sub-study.
FulvestrantDrug
Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle of main study and sub-study.
AlpelisibDrug
Alpelisib will be administered to participants at the approved dose in combination with fulvestrant: 300 mg taken PO QD and on days 1-28 of each 28-day cycle.
BupropionDrug
Participants will be administered bupropion PO on Day -3 and Day 12 of Cycle 1 of the sub-study.
OmeprazoleDrug
Participants will be administered omerprazole PO on Day -4 and Day 11 of Cycle 1 of sub-study.
MidazolamDrug
Participants will be administered midazolam PO on Day -4 and Day 11 of Cycle 1 of sub-study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blinded Independent Central Review (BICR)-Assessed Progression Free Survival (PFS)Time frame: From randomization until disease progression or death due to any cause (up to approximately 64 months)
- Sub-study: Maximum observed Drug Concentration (Cmax) for MidazolamTime frame: Day -4 and -3 of Cycle (C) 1, Day (D) 11 and C1D12. A cycle is 28 days.
- Sub-study: Cmax for BupropionTime frame: Day -3, -2, -1 of C1D1, C1D12, C1D13, C1D14 and C1D15. A cycle is 28 days.
- Sub-study: Cmax for OmeprazoleTime frame: Day -4 and -3 of C1D11 and C1D12. A cycle is 28 days.
- Sub-study: Area Under the Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUC [0-last]) for MidazolamTime frame: Day -4 and -3 of C1D11 and C1D12. A cycle is 28 days.
- Sub-study: AUC (0-last) for BupropionTime frame: Day -3, -2, -1 of C1D1, C1D12, C1D13, C1D14 and C1D15. A cycle is 28 days.
- Sub-study: AUC (0-last) for OmeprazoleTime frame: Day -4 and -3 of C1D11 and C1D12. A cycle is 28 days.
- Sub-study: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC [0-infinity]) for MidazolamTime frame: Day -4 and -3 of C1D11 and C1D12. A cycle is 28 days.
- Sub-study: AUC (0-infinity) for BupropionTime frame: Day -3, -2, -1 of C1D1, C1D12, C1D13, C1D14 and C1D15. A cycle is 28 days.
- Sub-study: AUC (0-infinity) for OmeprazoleTime frame: Day -4 and -3 of C1D11 and C1D12. A cycle is 28 days.
Locations
210 sites in 20 countries. Site status is shown where the registry gives one.
Marin Cancer Care Inc
Greenbrae, California · Withdrawn
Cancer Blood and Specialty Clinic
Los Alamitos, California · Active not recruiting
Los Angeles Cancer Network
Los Angeles, California · Active not recruiting
University of California, Irvine Medical Center
Orange, California · Withdrawn
UC Davis Comprehensive Cancer Center
Sacramento, California · Active not recruiting
Rocky Mountain Cancer Centers
Denver, Colorado · Completed
Banner MD Anderson Cancer Center
Greeley, Colorado · Withdrawn
Eastern CT Hematology and Oncology Associates
Norwich, Connecticut · Withdrawn
Cancer Care Centers of Brevard
Palm Bay, Florida · Withdrawn
Cleveland Clinic Florida
Weston, Florida · Active not recruiting
Grady Health System
Atlanta, Georgia · Active not recruiting
Midtown West Medical
Atlanta, Georgia · Active not recruiting
Emory University Hospital
Atlanta, Georgia · Recruiting
Winship Cancer Institute at Emory Saint Joseph's Hospital
Atlanta, Georgia · Active not recruiting
University of Louisville Hospital
Louisville, Kentucky · Withdrawn
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute.
Detroit, Michigan · Withdrawn
Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan · Completed
Minnesota Oncology Hematology
Saint Paul, Minnesota · Active not recruiting
MD Anderson Cancer Center at Cooper
Camden, New Jersey · Withdrawn
Novant Health Presbyterain Medical Center
Charlotte, North Carolina · Withdrawn
Novant Health Forsyth Medical Center
Winston-Salem, North Carolina · Withdrawn
Gabrail Cancer Center
Canton, Ohio · Withdrawn
Asante Rogue Regional Medical Center
Medford, Oregon · Completed
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania · Withdrawn
St. Lukes Hospital and Health Network
Easton, Pennsylvania · Withdrawn
Paoli Memorial Hospital
Paoli, Pennsylvania · Withdrawn
Abramson Cancer Center Chester County Hospital
West Chester, Pennsylvania · Withdrawn
Lankenau Medical Center, Cancer Center
Wynnewood, Pennsylvania · Withdrawn
Main Line Health System
Wynnewood, Pennsylvania · Withdrawn
WellSpan Oncology Research
York, Pennsylvania · Withdrawn
Texas Oncology West
Amarillo, Texas · Withdrawn
Texas Oncology - Dallas Presbyterian Hospital
Dallas, Texas · Active not recruiting
Texas Tech University Health Sciences Center
El Paso, Texas · Withdrawn
Texas Oncology (Flower Mound) - USOR
Flower Mound, Texas · Withdrawn
The Center for Cancer and Blood Disorders - Fort Worth
Fort Worth, Texas · Withdrawn
Lumi Research
Kingwood, Texas · Withdrawn
Texas Oncology McKinney
McKinney, Texas · Withdrawn
Kadlec Clinic Hematology and Oncology
Kennewick, Washington · Withdrawn
Centro de Investigaciones Médicas y Desarrollo LC S.R.L
Buenos Aires, Argentina · Completed
Showing 40 of 210 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.